Itron shares have declined 14.8% over the past six months to $84.38, underperforming the S&P 500's 8.4% gain. The company's revenue grew at a compounded annual rate of just 2.3% over the last five years, and Wall Street forecasts only 2.4% growth over the next twelve months. Its five-year average return on invested capital stands at 6.5%, well below the 20%-plus generated by top industrial firms. The stock trades at 14.5 times forward earnings, a valuation analysts consider reasonable but not compelling enough to recommend buying.
Itron IncStock fell 14.8% over six months, revenue growth slow at 2.3% CAGR, ROIC low at 6.5%, and analysts see limited upside at 14.5x forward earnings.